SCHEMBL16509244

SCHEMBL16509244

COc1ccc(-c2nc3ccc(C)cc3n2O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.51
ADORA1 P30542 1/20 0.51
KDM4E B2RXH2 9/20 0.49
HTT P42858 5/20 0.49
LMNA P02545 4/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
PKM P14618 1/20 0.49
MDM2 Q00987 1/20 0.49
SMN1; SMN2 Q16637 6/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
GAA P10253 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
CNR2 P34972 2/20 0.47
ALDH1A1 P00352 8/20 0.47
MAPT P10636 5/20 0.47
TP53 P04637 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16509196 0.92 ADORA3 (0.46) ADORA3ADORA1KDM4EHTTLMNA
SCHEMBL16509298 0.85 NPC1 (0.58) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL16509242 0.85 KDM4E (0.49) ADORA3ADORA1KDM4ELMNASMN1; SMN2
SCHEMBL16509322 0.83 MAPT (0.53) KDM4EHTTPKMSMN1; SMN2NPC1
SCHEMBL16509184 0.82 KDM4E (0.59) KDM4EMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL12325961 0.82 KDM4E (0.62) KDM4EHTTLMNAMEN1KMT2A
SCHEMBL12325734 0.82 KDM4E (0.65) KDM4EHTTLMNAMEN1KMT2A
SCHEMBL16509296 0.82 KDM4E (0.50) KDM4EHTTLMNAMEN1KMT2A
SCHEMBL16509324 0.82 NPC1 (0.50) KDM4EHTTLMNAMEN1KMT2A
SCHEMBL14922007 0.81 KDM4E (0.69) ADORA3ADORA1KDM4EHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306611-A1 Transcription factor modulating compounds and methods of use thereof PARATEK PHARMACEUTICALS, INC. (US) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306611-A1 Transcription factor modulating compounds and methods of use thereof JUN, CREBBP, TFEB ADORA3 4693/4885ADORA1 4723/4885KDM4E 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.